AbbVie, Amgen settlement sets Humira U.S. biosimilar launch for 2023

(Reuters) – Amgen Inc has reached a settlement with AbbVie Inc that will delay the U.S. launch of Amgen’s cheaper biosimilar version of AbbVie’s cash cow, the blockbuster rheumatoid arthritis drug Humira, until Jan. 31, 2023, the companies said on Thursday.


Source: Reuters Health News